Literature DB >> 20079710

Age-dependent and cell-population-restricted LRRK2 expression in normal mouse spleen.

Tatsunori Maekawa1, Makoto Kubo, Ikue Yokoyama, Etsuro Ohta, Fumiya Obata.   

Abstract

Leucine-rich repeat kinase 2 (LRRK2) is the causal molecule of familial Parkinson's disease (PD), but its true physiological function remains unknown. In the normal mouse, LRRK2 is expressed in kidney, spleen, and lung at much higher levels than in brain, suggesting that LRRK2 may play an important role in these organs. Analysis of age-related changes in LRRK2 expression demonstrated that expression in kidney, lung, and various brain regions was constant throughout adult life. On the other hand, expression of both LRRK2 mRNA and protein decreased markedly in spleen in an age-dependent manner. Analysis of purified spleen cells indicated that B lymphocytes were the major population expressing LRRK2, and that T lymphocytes showed no expression. Consistently, the B lymphocyte surface marker CD19 exhibited an age-dependent decrease of mRNA expression in spleen. These results suggest a possibly novel function of LRRK2 in the immune system, especially in B lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20079710     DOI: 10.1016/j.bbrc.2010.01.041

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  LRRK2 is involved in the IFN-gamma response and host response to pathogens.

Authors:  Agnès Gardet; Yair Benita; Chun Li; Bruce E Sands; Isabel Ballester; Christine Stevens; Joshua R Korzenik; John D Rioux; Mark J Daly; Ramnik J Xavier; Daniel K Podolsky
Journal:  J Immunol       Date:  2010-10-04       Impact factor: 5.422

2.  Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons.

Authors:  Nigel Ramsden; Jessica Perrin; Zhao Ren; Byoung Dae Lee; Nico Zinn; Valina L Dawson; Danny Tam; Michael Bova; Manja Lang; Gerard Drewes; Marcus Bantscheff; Frederique Bard; Ted M Dawson; Carsten Hopf
Journal:  ACS Chem Biol       Date:  2011-08-10       Impact factor: 5.100

3.  The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease.

Authors:  Zhihua Liu; Jinwoo Lee; Scott Krummey; Wei Lu; Huaibin Cai; Michael J Lenardo
Journal:  Nat Immunol       Date:  2011-10-09       Impact factor: 25.606

Review 4.  LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.

Authors:  A Raquel Esteves; Russell H Swerdlow; Sandra M Cardoso
Journal:  Exp Neurol       Date:  2014-06-04       Impact factor: 5.330

Review 5.  α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.

Authors:  Jason P Covy; Benoit I Giasson
Journal:  Neurotoxicology       Date:  2011-01-14       Impact factor: 4.294

6.  Synthesis and In Vitro and In Vivo Evaluation of [3H]LRRK2-IN-1 as a Novel Radioligand for LRRK2.

Authors:  Noeen Malik; Andrew N Gifford; Johan Sandell; Daniel Tuchman; Yu-Shin Ding
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

7.  Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures.

Authors:  Mansoureh Hakimi; Thirumahal Selvanantham; Erika Swinton; Ruth F Padmore; Youren Tong; Ghassan Kabbach; Katerina Venderova; Stephen E Girardin; Dennis E Bulman; Clemens R Scherzer; Matthew J LaVoie; Denis Gris; David S Park; Jonathan B Angel; Jie Shen; Dana J Philpott; Michael G Schlossmacher
Journal:  J Neural Transm (Vienna)       Date:  2011-05-07       Impact factor: 3.575

8.  Regulation of LRRK2 expression points to a functional role in human monocyte maturation.

Authors:  Jonathan Thévenet; Rosanna Pescini Gobert; Robertus Hooft van Huijsduijnen; Christoph Wiessner; Yves Jean Sagot
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

9.  Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.

Authors:  Chen Yao; William M Johnson; Yue Gao; Wen Wang; Jinwei Zhang; Maria Deak; Dario R Alessi; Xiongwei Zhu; John J Mieyal; Hanno Roder; Amy L Wilson-Delfosse; Shu G Chen
Journal:  Hum Mol Genet       Date:  2012-10-12       Impact factor: 6.150

10.  Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice.

Authors:  Florian Giesert; Andreas Hofmann; Alexander Bürger; Julia Zerle; Karina Kloos; Ulrich Hafen; Luise Ernst; Jingzhong Zhang; Daniela Maria Vogt-Weisenhorn; Wolfgang Wurst
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.